Elucidating the immunological function of the Cryptococcus neoformans capsule

Future Microbiology

Volumn 8, Issue 9, 2013, Pages 1107-1116

  Vecchiarelli, Anna ^a   Pericolini, Eva ^a   Gabrielli, Elena ^a   Kenno, Samyr ^a   Perito, Stefano ^a   Cenci, Elio ^a   Monari, Claudia ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

apoptosis; capsular polysaccharides; Cryptococcus neoformans; lymphocytes; macrophages; monocytes; signal transduction

Indexed keywords

GALACTOMANNAN; GALACTOXYLOMANNAN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; APOPTOSIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR IMMUNITY; CRYPTOCOCCUS NEOFORMANS; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFLAMMATION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

CRYPTOCOCCUS NEOFORMANS; HUMANS; IMMUNOLOGIC FACTORS; POLYSACCHARIDES; VIRULENCE FACTORS;

EID: 84884145300     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.84     Document Type: Review

References (85)

1. Perfect JR, Casadevall A. Cryptococcosis. Infect. Dis. Clin. North Am. 16(4), 837-874, v-vi (2002).
2. Idnurm A, Bahn YS, Nielsen K, Lin X, Fraser JA, Heitman J. Deciphering the model pathogenic fungus Cryptoccocus neoformans. Nat. Rev. Microbiol. 3(10), 753-764 (2005).
3. Nara S, Sano T, Ojima H et al. Liver cryptococcosis manifesting as obstructive jaundice in a young immunocompetent man: report of a case. Surg. Today 38(3), 271-274 (2008).
4. Durden FM, Elewski B. Cutaneous involvement with Cryptoccocus neoformans in AIDS. J. Am. Acad. Dermatol. 30(5 Pt 2), 844-848 (1994).
5. Sobel JD, Vazquez JA. Fungal infections of the urinary tract. World J. Urol. 17(6), 410-414 (1999).
6. Seaton RA, Verma N, Naraqi S, Wembri JP, Warrell DA. Visual loss in immunocompetent patients with Cryptoccocus neoformans var. gattii meningitis. Trans. R. Soc. Trop. Med. Hyg. 91(1), 44-49 (1997).
7. Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann. Rheum. Dis. 51(5), 690-697 (1992).
8. Kwon-Chung KJ, Varma A. Do major species concepts support one, two or more species within Cryptoccocus neoformans? FEMS Yeast Res. 6(4), 574-587 (2006).
9. Chang YC, Kwon-Chung KJ. Complementation of a capsule-deficient mutation of Cryptoccocus neoformans restores its virulence. Mol. Cell Biol. 14(7), 4912-4919 (1994).
10. Zhu X, Williamson PR. Role of laccase in the biology and virulence of Cryptoccocus neoformans. FEMS Yeast Res. 5(1), 1-10 (2004).
11. Perfect JR. Cryptoccocus neoformans: the yeast that likes it hot. FEMS Yeast Res. 6(4), 463-468 (2006).
12. Cox GM, McDade HC, Chen SC et al. Extracellular phospholipase activity is a virulence factor for Cryptoccocus neoformans. Mol. Microbiol. 39(1), 166-175 (2001).
13. Cox GM, Mukherjee J, Cole GT, Casadevall A, Perfect JR. Urease as a virulence factor in experimental cryptococcosis. Infect. Immun. 68(2), 443-448 (2000).
14. Qiu J, Olszewski M, Williamson PR. Cryptoccocus neoformans growth and protection from innate immunity is dependent on VAD1 expression. Infect. Immun. 81(3), 777-788 (2013).
15. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptoccocus neoformans infection. J. Clin. Microbiol. 37(10), 3204-3209 (1999).
16. Zhang Y, Wang F, Tompkins KC et al. Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptoccocus neoformans H99. Am. J. Pathol. 175(6), 2489-2500 (2009).
17. Tanaka M, Ishii K, Nakamura Y et al. Toll-like receptor 9-dependent activation of bone marrow-derived dendritic cells by URA5 DNA from Cryptoccocus neoformans. Infect. Immun. 80(2), 778-786 (2012).
18. Ishii K, Kawakami K. Pattern recognition and host defense response to Cryptoccocus neoformans. Med. Mycol. J. 53(4), 247-254 (2012).
19. Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM. Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptoccocus neoformans polysaccharide capsule. J. Immunol. 166(7), 4620-4626 (2001).
20. Piccioni M, Monari C, Bevilacqua S et al. A critical role for FcgammaRIIB in up-regulation of Fas ligand induced by a microbial polysaccharide. Clin. Exp. Immunol. 165(2), 190-201 (2011).
21. Gaffen SL, Hernandez-Santos N, Peterson AC. IL-17 signaling in host defense against Candida albicans. Immunol. Res. 50(2-3), 181-187 (2011).
22. Wozniak KL, Hardison SE, Kolls JK, Wormley FL. Role of IL-17A on resolution of pulmonary C. neoformans infection. PLoS ONE 6(2), e17204 (2011).
23. Arora S, Olszewski MA, Tsang TM, McDonald RA, Toews GB, Huffnagle GB. Effect of cytokine interplay on macrophage polarization during chronic pulmonary infection with Cryptoccocus neoformans. Infect. Immun. 79(5), 1915-1926 (2011).
24. Casadevall A, Pirofski LA. Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe 11(5), 447-456 (2012).
25. Beenhouwer DO, Yoo EM, Lai CW, Rocha MA, Morrison SL. Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptoccocus neoformans infection. Infect. Immun. 75(3), 1424-1435 (2007).
26. Cordero RJ, Pontes B, Frases S et al. Antibody binding to Cryptoccocus neoformans impairs budding by altering capsular mechanical properties. J. Immunol. 190(1), 317-323 (2013).
27. Janda A, Eryilmaz E, Nakouzi A, Cowburn D, Casadevall A. Variable region identical immunoglobulins differing in isotype express different paratopes. J. Biol. Chem. 287(42), 35409-35417 (2012).
28. Rosas AL, Nosanchuk JD, Casadevall A. Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptoccocus neoformans infection. Infect. Immun. 69(5), 3410-3412 (2001).
29. Rodrigues ML, Travassos LR, Miranda KR et al. Human antibodies against a purified glucosylceramide from Cryptoccocus neoformans inhibit cell budding and fungal growth. Infect. Immun. 68(12), 7049-7060 (2000).
30. Rachini A, Pietrella D, Lupo P et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptoccocus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect. Immun. 75(11), 5085-5094 (2007).
31. Gates MA, Thorkildson P, Kozel TR. Molecular architecture of the Cryptoccocus neoformans capsule. Mol. Microbiol. 52(1), 13-24 (2004).
32. Kozel TR, Cazin J. Nonencapsulated variant of Cryptoccocus neoformans I. Virulence studies and characterization of soluble polysaccharide. Infect. Immun. 3(2), 287-294 (1971).
33. Wilder JA, Olson GK, Chang YC, Kwon-Chung KJ, Lipscomb MF. Complementation of a capsule deficient Cryptoccocus neoformans with CAP64 restores virulence in a murine lung infection. Am. J. Respir. Cell Mol. Biol. 26(3), 306-314 (2002).
34. Zaragoza O, Rodrigues ML, De Jesus M, Frases S, Dadachova E, Casadevall A. The capsule of the fungal pathogen Cryptoccocus neoformans. Adv. Appl. Microbiol. 68, 133-216 (2009).
35. Feldmesser M, Kress Y, Novikoff P, Casadevall A. Cryptoccocus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect. Immun. 68(7), 4225-4237 (2000).
36. Dong F, Feldmesser M, Casadevall A, Rubin CS. Molecular characterization of a cDNA that encodes six isoforms of a novel murine A kinase anchor protein. J. Biol. Chem. 273(11), 6533-6541 (1998).
37. Reese AJ, Doering TL. Cell wall alpha-1,3-glucan is required to anchor the Cryptoccocus neoformans capsule. Mol. Microbiol. 50(4), 1401-1409 (2003).
38. Fonseca FL, Nimrichter L, Cordero RJ et al. Role for chitin and chitooligomers in the capsular architecture of Cryptoccocus neoformans. Eukaryot. Cell 8(10), 1543-1553 (2009).
39. McFadden DC, De Jesus M, Casadevall A. The physical properties of the capsular polysaccharides from Cryptoccocus neoformans suggest features for capsule construction. J. Biol. Chem. 281(4), 1868-1875 (2006).
40. Heiss C, Klutts JS, Wang Z, Doering TL, Azadi P. The structure of Cryptoccocus neoformans galactoxylomannan contains beta-d-glucuronic acid. Carbohydr. Res. 344(7), 915-920 (2009).
41. Heiss C, Skowyra ML, Liu H et al. Unusual galactofuranose modification of a capsule polysaccharide in the pathogenic yeast Cryptoccocus neoformans. J. Biol. Chem. 288(16), 10994-11003 (2013).
42. Frases S, Pontes B, Nimrichter L, Viana NB, Rodrigues ML, Casadevall A. Capsule of Cryptoccocus neoformans grows by enlargement of polysaccharide molecules. Proc. Natl Acad. Sci. USA 106(4), 1228-1233 (2009).
43. Nimrichter L, Frases S, Cinelli LP et al. Self-aggregation of Cryptoccocus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot. Cell 6(8), 1400-1410 (2007).
44. Kozel TR, Gotschlich EC. The capsule of Cryptoccocus neoformans passively inhibits phagocytosis of the yeast by macrophages. J. Immunol. 129(4), 1675-1680 (1982).
45. James PG, Cherniak R. Galactoxylomannans of Cryptoccocus neoformans. Infect. Immun. 60(3), 1084-1088 (1992).
46. Rodrigues ML, Nakayasu ES, Oliveira DL et al. Extracellular vesicles produced by Cryptoccocus neoformans contain protein components associated with virulence. Eukaryot. Cell 7(1), 58-67 (2008).
47. Nosanchuk JD, Nimrichter L, Casadevall A, Rodrigues ML. A role for vesicular transport of macromolecules across cell walls in fungal pathogenesis. Commun. Integr. Biol. 1(1), 37-39 (2008).
48. Grinsell M, Weinhold LC, Cutler JE, Han Y, Kozel TR. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptoccocus neoformans: a critical role for tissue macrophages. J. Infect. Dis. 184(4), 479-487 (2001).
49. Yauch LE, Mansour MK, Levitz SM. Receptor-mediated clearance of Cryptoccocus neoformans capsular polysaccharide in vivo. Infect. Immun. 73(12), 8429-8432 (2005).
50. Reiss E, Cherniak R, Eby R, Kaufman L. Enzyme immunoassay detection of IgM to galactoxylomannan of Cryptoccocus neoformans. Diagn. Immunol. 2(2), 109-115 (1984).
51. De Jesus M, Nicola AM, Rodrigues ML, Janbon G, Casadevall A. Capsular localization of the Cryptoccocus neoformans polysaccharide component galactoxylomannan. Eukaryot. Cell 8(1), 96-103 (2009).
52. Levitz SM, Specht CA. The molecular basis for the immunogenicity of Cryptoccocus neoformans mannoproteins. FEMS Yeast Res. 6(4), 513-524 (2006).
53. Vartivarian SE, Reyes GH, Jacobson ES et al. Localization of mannoprotein in Cryptoccocus neoformans. J. Bacteriol. 171(12), 6850-6852 (1989).
54. Mansour MK, Schlesinger LS, Levitz SM. Optimal T cell responses to Cryptoccocus neoformans mannoprotein are dependent on recognition of conjugated carbohydrates by mannose receptors. J. Immunol. 168(6), 2872-2879 (2002).
55. Cordero RJ, Pontes B, Guimaraes AJ et al. Chronological aging is associated with biophysical and chemical changes in the capsule of Cryptoccocus neoformans. Infect. Immun. 79(12), 4990-5000 (2011).
56. Ramos CL, Fonseca FL, Rodrigues J et al. Chitin-like molecules associate with Cryptoccocus neoformans glucuronoxylomannan to form a glycan complex with previously unknown properties. Eukaryot. Cell 11(9), 1086-1094 (2012).
57. Chaudhuri S, Gantner BN, Ye RD, Cianciotto NP, Freitag NE. The Listeria monocytogenes ChiA chitinase enhances virulence through suppression of host innate immunity. MBio 4(2), e00617-12 (2013).
58. Monari C, Kozel TR, Paganelli F et al. Microbial immune suppression mediated by direct engagement of inhibitory Fc receptor. J. Immunol. 177(10), 6842-6851 (2006).
59. Retini C, Vecchiarelli A, Monari C, Bistoni F, Kozel TR. Encapsulation of Cryptoccocus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect. Immun. 66(2), 664-669 (1998).
60. Monari C, Pericolini E, Bistoni G, Casadevall A, Kozel TR, Vecchiarelli A. Cryptoccocus neoformans capsular glucuronoxylomannan induces expression of Fas ligand in macrophages. J. Immunol. 174(6), 3461-3468 (2005).
61. Villena SN, Pinheiro RO, Pinheiro CS et al. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptoccocus neoformans induce macrophage apoptosis mediated by Fas ligand. Cell. Microbiol. 10(6), 1274-1285 (2008).
62. Vecchiarelli A, Retini C, Monari C, Tascini C, Bistoni F, Kozel TR. Purified capsular polysaccharide of Cryptoccocus neoformans induces interleukin-10 secretion by human monocytes. Infect. Immun. 64(7), 2846-2849 (1996).
63. Monari C, Bistoni F, Vecchiarelli A. Glucuronoxylomannan exhibits potent immunosuppressive properties. FEMS Yeast Res. 6(4), 537-542 (2006).
64. Chiapello LS, Baronetti JL, Garro AP, Spesso MF, Masih DT. Cryptoccocus neoformans glucuronoxylomannan induces macrophage apoptosis mediated by nitric oxide in a caspase-independent pathway. Int. Immunol. 20(12), 1527-1541 (2008).
65. Monari C, Bistoni F, Casadevall A et al. Glucuronoxylomannan, a microbial compound, regulates expression of co-stimulatory molecules and production of cytokines in macrophages. J. Infect. Dis. 191(1), 127-137 (2005).
66. Monari C, Bevilacqua S, Piccioni M et al. A microbial polysaccharide reduces the severity of rheumatoid arthritis by influencing Th17 differentiation and proinflammatory cytokines production. J. Immunol. 183(1), 191-200 (2009).
67. Piccioni M, Monari C, Kenno S et al. A purified capsular polysaccharide markedly inhibits inflammatory response during endotoxic shock. Infect. Immun. 81(1), 90-98 (2013).
68. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 1(6), a001651 (2009).
69. Moyrand F, Fontaine T, Janbon G. Systematic capsule gene disruption reveals the central role of galactose metabolism on Cryptoccocus neoformans virulence. Mol. Microbiol. 64(3), 771-781 (2007).
70. Gadebusch HH. Passive immunization against Cryptoccocus neoformans. Proc. Soc. Exp. Biol. Med. 98(3), 611-614 (1958).
71. De Jesus M, Nicola AM, Frases S, Lee IR, Mieses S, Casadevall A. Galactoxylomannan-mediated immunological paralysis results from specific B cell depletion in the context of widespread immune system damage. J. Immunol. 183(6), 3885-3894 (2009).
72. Pericolini E, Gabrielli E, Cenci E et al. Involvement of glycoreceptors in galactoxylomannan-induced T cell death. J. Immunol. 182(10), 6003-6010 (2009).
73. Lakhani S, Flavell RA. Caspases and T lymphocytes: a flip of the coin? Immunol. Rev. 193, 22-30 (2003).
74. Pericolini E, Gabrielli E, Bistoni G et al. Role of CD45 signaling pathway in galactoxylomannan-induced T cell damage. PLoS ONE 5(9), e12720 (2010).
75. Mustelin T, Tasken K. Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochem. J. 371(Pt 1), 15-27 (2003).
76. McNeill L, Salmond RJ, Cooper JC et al. The differential regulation of Lck kinase phosphorylation sites by CD45 is critical for T cell receptor signaling responses. Immunity 27(3), 425-437 (2007).
77. Harr MW, Caimi PF, McColl KS et al. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Cell Death Differ. 17(9), 1381-1391 (2010).
78. Pericolini E, Alunno A, Gabrielli E et al. The microbial capsular polysaccharide galactoxylomannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients. PLoS ONE 8(1), e53336 (2013).
79. Islander U, Jochems C, Lagerquist MK, Forsblad-d'Elia H, Carlsten H. Estrogens in rheumatoid arthritis; the immune system and bone. Mol. Cell Endocrinol. 335(1), 14-29 (2011).
80. Murphy JW. Influence of cryptococcal antigens on cell-mediated immunity. Rev. Infect. Dis. 10(Suppl. 2), S432-S435 (1988).
81. Levitz SM, Nong S, Mansour MK, Huang C, Specht CA. Molecular characterization of a mannoprotein with homology to chitin deacetylases that stimulates T cell responses to Cryptoccocus neoformans. Proc. Natl Acad. Sci. USA 98(18), 10422-10427 (2001).
82. Specht CA, Nong S, Dan JM, Lee CK, Levitz SM. Contribution of glycosylation to T cell responses stimulated by recombinant Cryptoccocus neoformans mannoprotein. J. Infect. Dis. 196(5), 796-800 (2007).
83. Eigenheer RA, Jin Lee Y, Blumwald E, Phinney BS, Gelli A. Extracellular glycosylphosphatidylinositol-anchored mannoproteins and proteases of Cryptoccocus neoformans. FEMS Yeast Res. 7(4), 499-510 (2007).
84. Chaka W, Verheul AF, Vaishnav VV et al. Induction of TNF-alpha in human peripheral blood mononuclear cells by the mannoprotein of Cryptoccocus neoformans involves human mannose binding protein. J. Immunol. 159(6), 2979-2985 (1997).
85. Cadieux B, Lian T, Hu G et al. The mannoprotein Cig1 supports iron acquisition from heme and virulence in the pathogenic fungus Cryptoccocus neoformans. J. Infect. Dis. 207(8), 1339-1347 (2013).